These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

106 related articles for article (PubMed ID: 23453596)

  • 1. Cost-effectiveness of pharmacological treatment of attention deficit hyperactivity disorder in children and adolescents: qualitative synthesis of scientific evidence.
    Catalá-López F; Ridao M; Sanfélix-Gimeno G; Peiró S
    Rev Psiquiatr Salud Ment; 2013; 6(4):168-77. PubMed ID: 23453596
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cost effectiveness of pharmacotherapies for attention-deficit hyperactivity disorder: a systematic literature review.
    Wu EQ; Hodgkins P; Ben-Hamadi R; Setyawan J; Xie J; Sikirica V; Du EX; Yan SY; Erder MH
    CNS Drugs; 2012 Jul; 26(7):581-600. PubMed ID: 22712698
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A modeled economic evaluation comparing atomoxetine with stimulant therapy in the treatment of children with attention-deficit/hyperactivity disorder in the United Kingdom.
    Cottrell S; Tilden D; Robinson P; Bae J; Arellano J; Edgell E; Aristides M; Boye KS
    Value Health; 2008; 11(3):376-88. PubMed ID: 18489664
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Assessing the value of atomoxetine in treating children and adolescents with ADHD in the UK.
    Prasad S; Arellano J; Steer C; Libretto SE
    Int J Clin Pract; 2009 Jul; 63(7):1031-40. PubMed ID: 19570121
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A Cost-Utility Analysis of Lisdexamfetamine Versus Atomoxetine in the Treatment of Children and Adolescents with Attention-Deficit/Hyperactivity Disorder and Inadequate Response to Methylphenidate.
    Zimovetz EA; Beard SM; Hodgkins P; Bischof M; Mauskopf JA; Setyawan J
    CNS Drugs; 2016 Oct; 30(10):985-96. PubMed ID: 27530525
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Health care costs of adults treated for attention-deficit/hyperactivity disorder who received alternative drug therapies.
    Wu EQ; Birnbaum HG; Zhang HF; Ivanova JI; Yang E; Mallet D
    J Manag Care Pharm; 2007 Sep; 13(7):561-9. PubMed ID: 17874862
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Comparative efficacy and acceptability of atomoxetine, lisdexamfetamine, bupropion and methylphenidate in treatment of attention deficit hyperactivity disorder in children and adolescents: a meta-analysis with focus on bupropion.
    Stuhec M; Munda B; Svab V; Locatelli I
    J Affect Disord; 2015 Jun; 178():149-59. PubMed ID: 25813457
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Systematic evidence synthesis of treatments for ADHD in children and adolescents: indirect treatment comparisons of lisdexamfetamine with methylphenidate and atomoxetine.
    Roskell NS; Setyawan J; Zimovetz EA; Hodgkins P
    Curr Med Res Opin; 2014 Aug; 30(8):1673-85. PubMed ID: 24627974
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Is adjunctive pharmacotherapy in attention-deficit/hyperactivity disorder cost-effective in Canada: a cost-effectiveness assessment of guanfacine extended-release as an adjunctive therapy to a long-acting stimulant for the treatment of ADHD.
    Lachaine J; Sikirica V; Mathurin K
    BMC Psychiatry; 2016 Jan; 16():11. PubMed ID: 26774811
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The pharmacological and non-pharmacological treatment of attention deficit hyperactivity disorder in children and adolescents: A systematic review with network meta-analyses of randomised trials.
    Catalá-López F; Hutton B; Núñez-Beltrán A; Page MJ; Ridao M; Macías Saint-Gerons D; Catalá MA; Tabarés-Seisdedos R; Moher D
    PLoS One; 2017; 12(7):e0180355. PubMed ID: 28700715
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Probabilistic Markov Model Estimating Cost Effectiveness of Methylphenidate Osmotic-Release Oral System Versus Immediate-Release Methylphenidate in Children and Adolescents: Which Information is Needed?
    Schawo S; van der Kolk A; Bouwmans C; Annemans L; Postma M; Buitelaar J; van Agthoven M; Hakkaart-van Roijen L
    Pharmacoeconomics; 2015 May; 33(5):489-509. PubMed ID: 25715975
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Treatment of Attention-Deficit/Hyperactivity Disorder in Adolescents: A Systematic Review.
    Chan E; Fogler JM; Hammerness PG
    JAMA; 2016 May; 315(18):1997-2008. PubMed ID: 27163988
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Children's relative age in class and medication for attention-deficit/hyperactivity disorder. A population-based study in a health department in Spain].
    Librero J; Izquierdo-María R; García-Gil M; Peiró S
    Med Clin (Barc); 2015 Dec; 145(11):471-6. PubMed ID: 25913908
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Methylphenidate in the treatment of attention-deficit/hyperactivity disorder: are we achieving an adequate clinical practice?].
    Gonzalez de Dios J; Cardó E; Servera M
    Rev Neurol; 2006 Dec 16-31; 43(12):705-14. PubMed ID: 17160919
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Priapism associated with the use of stimulant medications and atomoxetine for attention-deficit/hyperactivity disorder in children.
    Eiland LS; Bell EA; Erramouspe J
    Ann Pharmacother; 2014 Oct; 48(10):1350-5. PubMed ID: 24982313
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Is NICE infallible? A qualitative study of its assessment of treatments for attention-deficit/hyperactivity disorder (ADHD).
    Schlander M
    Curr Med Res Opin; 2008 Feb; 24(2):515-35. PubMed ID: 18186971
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A cost-effectiveness analysis of off-label atypical antipsychotic treatment in children and adolescents with ADHD who have failed stimulant therapy.
    Sohn M; Talbert J; Moga DC; Blumenschein K
    Atten Defic Hyperact Disord; 2016 Sep; 8(3):149-58. PubMed ID: 27143026
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Differences in Utilization Patterns among Medications in Children and Adolescents with Attention-Deficit/Hyperactivity Disorder: a 36-Month Retrospective Study Using the Korean Health Insurance Review and Assessment Claims Database.
    Bhang SY; Hwang JW; Kwak YS; Joung YS; Lee S; Kim B; Sohn SH; Chung US; Yang J; Hong M; Bahn GH; Choi HY; Oh IH; Lee YJ
    J Korean Med Sci; 2016 Aug; 31(8):1284-91. PubMed ID: 27478341
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Evolution of stress in families of children with attention deficit hyperactivity disorder].
    Guerro-Prado D; Mardomingo-Sanz ML; Ortiz-Guerra JJ; García-García P; Soler-López B
    An Pediatr (Barc); 2015 Nov; 83(5):328-35. PubMed ID: 25683274
    [TBL] [Abstract][Full Text] [Related]  

  • 20. An Open-Label, Randomized Trial of Methylphenidate and Atomoxetine Treatment in Children with Attention-Deficit/Hyperactivity Disorder.
    Shang CY; Pan YL; Lin HY; Huang LW; Gau SS
    J Child Adolesc Psychopharmacol; 2015 Sep; 25(7):566-73. PubMed ID: 26222447
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.